Cellceutix: The Next Ten-Bagger Or Pie-In-The-Sky? by InvestorR
Cellceutix (CTIX.OB) trades on the OTC Bulletin Board, with a market cap of $172M [for key stats, see yahoo] at the time of writing this. It has slightly under 100M shares outstanding and has traded in the last 3 months more or less between $1.50 and $2.30 judging by the charts [one has less confidence about the price figures for unlisted stocks]. The price, a year ago, was about 70¢/sh. What is behind such rise is the interesting question, as well as where it is headed. Such a lofty valuation for a biotech firm that still has not published any clinical data on efficacy, has only $1M in cash, and has $2M in debt means that all of the company's valuation is based on its prospects. The stock has been in a clear uptrend and has risen ten-fold from the beginning of 2011. As a biotech speculator who is long this stock, I wrote this review for my own sake to see if I had bought into a lot of hype, or into real block-buster potential. I present the pros and cons here (without grouping them as such) for you to judge, although, having reviewed and studied the relevant information, I think its case for big-time breakthrough in cancer therapy is very strong.
Market Data 
Markets 
AI
